H.C. Wainwright analyst Douglas Tsao maintained a Buy rating on Protagonist Therapeutics (NASDAQ:PTGX) on Monday, setting a price target of $50, which is approximately 34.77% above the present share price of $37.1.
Tsao expects Protagonist Therapeutics to post earnings per share (EPS) of -$0.70 for the fourth quarter of 2021.
The current consensus among 7 TipRanks analysts is for a Strong Buy rating of shares in Protagonist Therapeutics, with an average price target of $59.71.
The analysts price targets range from a high of $93 to a low of $40.
In its latest earnings report, released on 09/30/2021, the company reported a quarterly revenue of $10.29 million and a net profit of -$33.93 million. The company's market cap is $1.77 billion.
According to TipRanks.com, H.C. Wainwright analyst Douglas Tsao is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 12.4% and a 50.36% success rate.
Protagonist Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of novel constrained peptide-based drug candidates that address significant unmet medical needs. The firm's initial lead product candidates, PTG-100 and PTG-200, are being developed for moderate-to-severe ulcerative colitis and Crohn's disease, respectively. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.